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Background: This study investigated the survival benefits of sorafenib vs. radiotherapy (RT) in patients with
unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in the main trunk or the first
branch.
Methods: Ninety-seven patients were retrospectively reviewed. Forty patients were enrolled by the Kanagawa Liver
Study Group and received sorafenib, and 57 consecutive patients received RT in our hospital. Overall survival was
compared between the two groups with PVTT by propensity score (PS) analysis. Factors associated with survival
were evaluated by multivariate analysis.
Results: The median treatment period with sorafenib was 45 days, while the median total radiation dose was
50 Gy. The Child-Pugh class and the level of invasion into hepatic large vessels were significantly more advanced in
the RT group than in the sorafenib group. Median survival did not differ significantly between the sorafenib group
(4.3 months) and the RT group (5.9 months; P = 0.115). After PS matching (n = 28 per group), better survival was
noted in the RT group than in the sorafenib group (median survival, 10.9 vs. 4.8 months; P = 0.025). A Cox model
showed that des-γ-carboxy prothrombin <1000 mAU/mL at enrollment and RT were significant independent
predictors of survival in the PS model (P = 0.024, HR, 0.508; 95% CI, 0.282 to 0.915; and P = 0.007, HR, 0.434; 95%
CI, 0.235 to 0.779; respectively).
Conclusions: RT is a better first-line therapy than sorafenib in patients who have advanced unresectable HCC
with PVTT.
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Hepatocellular carcinoma (HCC) recurs frequently after
curative treatment [1-4]. Advanced HCC sometimes
causes macroscopic hepatic vascular invasion, including
portal vein tumor thrombosis (PVTT) in the main portal
trunk or the first branch and venous thrombosis in the hep-
atic vein trunk or inferior vena cava. These conditions can* Correspondence: tnakazaw@kitasato-u.ac.jp
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unless otherwise stated.be life threatening, and the prognosis of patients with
PVTT remains very poor, with a median survival of only
approximately 3 months without treatment [5-8]. There-
fore, identification of effective treatments that are not asso-
ciated with significant adverse effects would be of benefit
for this patient population. Transarterial chemoemboliza-
tion (TACE) is one treatment for advanced HCC and is as-
sociated with an increased risk of ischemic necrosis of the
liver and of treatment-related death in patients with PVTT.
Therefore, this strategy is limited to a select group of pa-
tients with good hepatic function, patients with PVTT
other than in the main or the first branch, and those withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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vein. Other treatment options include hepatic infusion
chemotherapy mainly with 5-fluorouracil and cisplatin with
or without interferon [9-11]. However, the efficacy of such
treatments is limited, and this regimen can cause consider-
able stress for patients.
The use of molecular targeted therapy continues to in-
crease. Sorafenib is an oral multikinase inhibitor with
antiangiogenic and antiproliferative effects that signifi-
cantly improves time-to-tumor progression and overall
survival (OS) of patients with advanced HCC and is
widely used to treat advanced HCC in which curative
therapy is not indicated [12-14]. Sorafenib inhibits sev-
eral tyrosine kinase receptors, including vascular endo-
thelial growth factor (VEGF) receptor (R)-2, VEGFR-3,
platelet-derived growth factor receptor β, FLT-3, and
C-kit [15]. Although the use of sorafenib is limited to a
select group of patients with good hepatic function, it
can also be effective for patients with advanced HCC
and a poor prognosis, including those with worse ECOG
performance status, extrahepatic spread, vascular inva-
sion, older age, and presence of macroscopic vascular
invasion or extrahepatic spread [12]. However, care
must be exercised due to the fact that sorafenib fre-
quently causes various adverse events (AEs) such as
hand-foot syndrome, gastrointestinal hemorrhage, and
use-limiting anorexia [12-14].
Radiotherapy (RT) can produce survival benefits in pa-
tients with advanced HCC and macroscopic hepatic vas-
cular invasion [7,16-18]. We previously reported that the
use of three-dimensional conformal RT (3D-CRT) re-
sulted in a good disease control rate and prolonged
survival in these patients. Because of a high induction
rate of stable disease (SD), both responders and nonre-
sponders had improved outcomes when compared with
patients who received supportive care alone [8,17]. An-
other advantage of 3D-CRT is that treatment can be ad-
ministered on an outpatient basis without the difficulties
associated with TACE or hepatic infusion chemotherapy,
and RT did not produce grade 3 or higher liver, gastro-
intestinal, or hematological toxicity [8,17].
The goal of the present study was to compare the sur-
vival benefit of sorafenib versus RT in two retrospective
cohorts of patients with advanced HCC and PVTT in
the main trunk or the first branch. Propensity score ana-
lysis was used to reduce biases, and potential predictors
of survival were analyzed using a Cox model.
Methods
Study population
Ninety-seven patients with macroscopic hepatic vascular
invasion were retrospectively reviewed following approval
by the institutional review board at Kitasato University East
Hospital. Study protocols were conducted in accordancewith the principles of the Declaration of Helsinki. All
patients provided written, informed consent. HCC with
macroscopic hepatic vascular invasion included patients
with portal tumor invasion involving first-order branches
and the main trunk of the portal vein, and venous throm-
bosis in the hepatic vein trunk or inferior vena cava. A diag-
nosis of tumor invasion and macroscopic hepatic vascular
invasion was established in all patients by computed tom-
ography (CT) on the basis of the following criteria: (i) a
low-attenuation intraluminal filling defect with expanded
macroscopic hepatic vascular invasion adjacent to the pri-
mary tumor during the portal phase, and (ii) an enhanced
inner side of the filling defect during the arterial phase.
Forty patients treated with sorafenib enrolled in the Kana-
gawa Liver Study Group (four institutes in Kanagawa Pre-
fecture in Japan) and 57 consecutive HCC patients treated
with RT in Kitasato University East Hospital (Sagamihara,
Kanagawa, Japan) were examined. Overall survival (OS)
and AEs were compared between the two groups of the en-
tire cohort and in a PS-matched cohort. Factors potentially
associated with OS were analyzed statistically in a PS-
matched model. Treatment response was not compared,
because the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria (version 1.1) and the modified RECIST
criteria, which are commonly used for patients with HCC
treated with sorafenib, were not adapted for use in patients
with macroscopic hepatic vascular invasion [19,20]. The
follow-up period was from initiation of treatment to the
time of death. AEs were assessed according to the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events, version 4.0.Sorafenib group
From July 2009 through November 2011, a total of 40
patients with advanced HCC with macroscopic hepatic
vascular invasion and chronic liver disease of mainly
Child-Pugh (C-P) class A received sorafenib at four
institutes in Kanagawa Prefecture in Japan (Kitasato
University East Hospital, Sagamihara; Yokohama City
University Hospital, Yokohama; St. Marianna University
Hospital, Kawasaki, and Kanagawa Cancer Center,
Yokohama). Eligibility criteria for treatment with sorafenib
were as follows: (i) unresectable advanced HCC without
HCC rupture; (ii) no effect of TACE; (iii) no previous soraf-
enib therapy for the liver tumor; (iv) C-P class A or B (up
to a score of 7 points) hepatic function; (v) an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0–2 [21]; and (vi) the following laboratory findings:
neutrophil count above 1500/μL, platelet count above 7.5 ×
104 mm3, and serum hemoglobin level above 8.5 g/dL.
Patients initially received a standard dose of sorafenib,
400 mg twice daily (800 mg/day) or 200 mg twice daily
(400 mg/day) for those with low body weight. The dose
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in patients who had drug-related grade 2–4 toxicities
(until recovery to grade 1 or less) or at the discretion
of the treating physician. The initial reduced dose of
sorafenib was 400 mg/day. The dose was increased to
the standard dose level in accordance with each pa-
tient’s tolerance. Treatment was continued until radio-
logic progression or recurrence of HCC, unacceptable
toxicity associated with the study drug, or withdrawal
of consent.
RT group
From July 2001 through November 2011, 57 consecutive
patients with advanced HCC and macroscopic hepatic
vascular invasion initially received 3D-CRT at Kitasato
University East Hospital, Sagamihara, Japan. Inclusion
criteria for patients who received RT were as follows: (i)
unresectable HCC with macroscopic hepatic vascular in-
vasion; (ii) C-P class A or B hepatic function; (iii) an
ECOG performance status of 0–2; (iv) no refractory asci-
tes; and (v) no previous radiation therapy of the liver.
The RT procedure was performed as described previ-
ously [8,17]. Briefly, macroscopic hepatic vascular inva-
sion was mainly irradiated, regardless of the presence or
absence of multinodular HCC. RT doses and treatment
angles were determined with the use of a 3D-view tech-
nique to minimize critical organ injury. CT planning
was used to determine radiation fields and the clinical
target volume (CTV), which was defined as only the
macroscopic hepatic vascular invasion. The main HCC
was also irradiated together with hepatic vascular inva-
sion if the tumor was directly involved. Other multiple





















Figure 1 Kaplan-Meier curves for OS of the RT (bold lines) and sorafe
patients (n = 56). Although no significant difference between the two grou
significantly longer in the RT group (median 10.9 months) than in the sorafenibwas planned according to tentative guidelines to ensure
that the normal liver volume irradiated with more than
one half of the prescribed dose did not exceed 50% of
the total liver volume. A daily radiation dose of 1.8 to
2.0 Gy was administered with a 6- or 10-MV X-rays
using two- to four-port combinations. Five fractions
were administered per week to deliver a total dose of
around 50 Gy.
Statistical analysis
The overall survival rates of patients who underwent so-
rafenib or RT were calculated from the date of diagnosis
of macroscopic hepatic vascular invasion. The primary
end point was all-cause mortality. The Chi-square or
Fisher’s exact test was used to compare categorical vari-
ables, whereas Student’s t-test or the Mann–Whitney U test
was used for continuous variables. The Kaplan-Meier
method was used to obtain the cumulative survival rate. PS
analysis was performed using multiple logistic regression to
analyze patients treated with sorafenib or RT. Variables as-
sociated with treatment decisions were entered in the PS
model. The PS model was then used to provide a one-to-
one match between the sorafenib and RT groups by the
nearest-neighbor matched method [22]. In each matched
subgroup, survival curves were compared using the log-
rank test. Variables that achieved significance (P < 0.05) or
those that were close to significance (P < 0.15) by the log-
rank test were subsequently included in the multivariate
analysis using a forward stepwise Cox regression model for
the analysis of factors associated with OS, with adjustments
for confounding factors. A two-tailed P < 0.05 was consid-










nib (solid lines) groups. (a), all patients (n = 97) and (b), PS-matched
ps is observed in (a) (P = 0.115), OS in the PS-matched patients is
group (median 4.8 months), as shown in (b) (P= 0.002, log-rank test).
Table 1 Baseline characteristics of 64 patients with Child-Pugh class A and 56 patients matched by propensity score
Entire cohort PS-matched cohort
Sorafenib RT P value Sorafenib RT P value
Covariates n = 36 n = 28 n = 28 n = 28
Age (years) 70 (62–78) 67 (61–71) 0.069 70 (61–78) 67 (61–70) 0.04
Sex (male/female) 31/5 19/9 0.127 23/5 19/9 0.355
HCV 19/17 17/11 0.615 16/12 17/11 1.0
*Main/first branch 7/29 9/19 0.262 7/24 9/19 0.205
Metastases (present/absent) 7/29 2/26 0.278 6/22 2/26 0.252
Previous Treatments (present/absent) 26/10 20/8 1.0 18/10 20/8 0.775
TACE/TAI 21 20 15 20
RFA 3 0 2 0
RT 2 0 1 0
AFP (ng/dL) 1047 (44–5919) 43 (10–1096) 0.005 680 (37–3708) 43 (10–1096) 0.144
DCP (mAU/mL) 2915 (111–19706) 224 (33–2880) 0.013 2151 (58–10775) 224 (33–2880) 0.488
Data are presented as medians (range).
Abbreviations: TACE transarterial chemoembolization, TAI transarterial infusion chemotherapy, RFA radiofrequency ablation, RT radiotherapy, HCV hepatitis C virus,
AFP α-fetoprotein, DCP des-γ-carboxy prothrombin, AST aspartate aminotransferase, ALT alanine aminotransferase, PS propensity score.
*Portal tumor invasion to the main trunk or first branch.
Patients with advanced HCC and 
macroscopic hepatic vascular invasion
(n = 97, sorafenib/RT 40/57) 
Exclusion (n = 33)
Child-Pugh class B (n = 27)
PVTT combined with HVTT (n = 6)
Propensity score analysis
(n = 64, sorafenib/RT 36/28)
Figure 2 Enrollment of patients. HCC: hepatocellular carcinoma;
RT: radiotherapy; PVTT: portal vein tumor thrombosis; HVTT: hepatic
vein tumor thrombosis.
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for Windows, SPSS, Inc. Chicago, IL).
Results
Patient characteristics and crude OS in response to
sorafenib versus RT
All patients (n = 97) underwent either sorafenib (n = 40) or
RT (n = 57) treatment. In the sorafenib group, 28 patients
initially received a dose 400 mg of sorafenib twice daily
(800 mg/day), while 12 received a dose of 200 mg of sorafe-
nib twice daily (400 mg/day) because of older age, low body
mass index, or anorexia. The mean duration of treatment
with sorafenib was 45 days (range, 7–400 days).
A total radiation dose of 30 to 56 Gy (median 50 Gy) was
delivered, and a combination of PVTT and hepatic vein
tumor thrombosis (HVTT) was observed in 10 patients in
the RT group. The sorafenib group had significantly better
hepatic function of C-P class A/B (sorafenib 36/4 and
RT 34/23 patients, respectively, P = 0.001) and median
platelet counts than the RT group (sorafenib 15.1 and RT
11.8 × 104/mm3, respectively, P = 0.004). Tumor thrombosis
in the main portal trunk was significantly more common in
the RT group than in the sorafenib group (main/first
branch: sorafenib 7/33 and RT 22/35 patients, respectively,
P = 0.021). Otherwise, age, sex, the proportions of anti-
hepatitis C virus-positive and of extrahepatic spread, and
the median values of laboratory findings including α-
fetoprotein and des-γ-carboxy prothrombin were not sig-
nificantly different between the two groups. Thirty-three
patients treated with sorafenib died (83%), while 57 treated
with RT died during the observation period. Despite the
fact that the RT study population had significant worsening
of hepatic function and tumor progression in comparisonwith the sorafenib group, crude OS was not significantly
different between the two groups [P = 0.115, 4.4 months
(range, 0.7-17.5) in the sorafenib group, and 5.9 months
(range, 0.6-103) in the RT group], as shown in Figure 1a.
OS and factors related to OS in the PS-matched
population
A total of 64 patients with C-P class A hepatic function
and PVTT only. (sorafenib; n = 36, RT; n = 28) was ex-
tracted for PS analyses, as shown in Table 1 and Figure 2.
Six of the 34 RT group patients with C-P class A were ex-
cluded because they had a combination of PVTT and
HVTT. Significant differences between these two groups
were observed in baseline levels of the tumor markers α-
fetoprotein and des-γ-carboxy prothrombin (DCP). PS ana-
lysis with the one-to-one nearest-neighbor matching
Table 2 Cox regression analysis of factors potentially related to overall survival
Log-rank test Cox
Covariates n P value P value HR 95% CI
Age (≥70/<70 y) 33/23 0.355
Sex (male/female) 42/14 0.424
HCV (present/absent) 34/22 0.58
*Main trunk (present/absent) 16/40 0.612
Extrahepatic spread (present/absent) 5/51 0.278
Previous treatments (present/absent) 38/18 0.546
AFP≥ 100 (ng/dL) 28/28 0.073
DCP≥ 1000 (mAU/mL) 27 0.066 0.024 1
<1000 29 0.508 0.282, 0.915
Sorafenib 28 0.002 0.007 1
RT 28 0.434 0.235, 0.779
Abbreviations: HCV hepatitis C virus, AFP α-fetoprotein, DCP des-γ-carboxy prothrombin, RT radiotherapy, HR hazard ratio, CI confidence interval.
*Portal invasion to the main trunk.
Table 3 Comparison of AEs between sorafenib and RT
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adjust backgrounds. The two PS-matched groups (28 pa-
tients per group) were well balanced, as shown in Table 1.
The PS-matched model was validated by the Hosmer and
Lemeshow goodness-of-fit test (P = 0.091) and by the value
of the area under the curve (0.719; 95% CI, 0.594-0.844). In
the PS-matched cohort, the median OS was significantly
shorter in the sorafenib group (4.8 months; range, 0.7-17.3)
than in the RT group (10.9 months; range, 2.8-103; P =
0.002, log-rank test), as shown in Figure 1b. Cox regression
analyses showed that DCP <1000 mAu/mL at pretreatment
and RT were independent contributors to OS (P = 0.024;
HR, 0.508; 95% CI, 0.282 to 0.915; P = 0.007; HR, 0.434;
95% CI, 0.235 to 0.779, respectively) (Table 2).Sorafenib RT
Grade 3/4 toxicity
Total (n) 19 1
AST/ALT increased 6 0
Anorexia/nausea 4 0
HFSR 3 0









Discontinuation, n (%) 15 (54) 1 (4)
Abbreviations: AEs adverse events, AST aspartate aminotransferase, ALT alanine
aminotransferase, RT radiotherapy, HFSR hand-foot-skin reaction.Treatment tolerability
Treatment tolerability was analyzed by comparison of
the AEs between the sorafenib and RT groups matched
according to PS score. In the sorafenib group, 25 (90%)
of 28 patients permanently discontinued sorafenib
(due to AEs, n = 15; disease progression, n = 10). There
was no radiographic or clinical evidence of pancrea-
titis, and there were no drug-related deaths. As shown
in Table 3, AEs of grade 3 or more were observed in 19
patients, and almost all AEs were related to the liver
(AST/ALT increase in six patients, anorexia/nausea in
four patients, hepatic failure in one patient, and ascites
in one patient). In the RT group, there was no grade 3
or higher gastrointestinal or hepatic toxicity, including
anorexia/nausea, gastric ulcer, increase in AST/ALT,
or hepatic failure. Grade 3 leukocytopenia was ob-
served in only one patient. There were no long-term
sequelae.Discussion
PS analysis demonstrated that RT was associated with
better survival than sorafenib in patients with advanced
unresectable HCC and PVTT. PVTT occurs in a sub-
stantial portion of HCC patients and is evident in up to
approximately 40% of HCC patients at the time of death
[7,9,23]. Sorafenib is an oral multikinase inhibitor that
prolongs survival and the time to progression in patients
with advanced HCC. This drug is also effective in patients
with advanced HCC and poor prognosis, including those
with worse ECOG performance status, extrahepatic spread,
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scopic vascular invasion or extrahepatic spread [12]. In a
recent PS analysis of sorafenib alone versus sorafenib com-
bined with TACE for advanced HCC (in which 20-30% of
the patient population had major trunk PVTT), neither
regimen produced a significant benefit in OS [24]. We
previously reported that RT produced favorable sur-
vival benefits without the hardships associated with
conventional treatment for macroscopic hepatic vascu-
lar invasion [8,17].
The current study demonstrated that DCP <1000
mAu/mL at pretreatment and RT were independently
related to OS, according to a Cox model in a PS analysis.
The serum DCP level correlates with intrahepatic vas-
cular invasion, and the DCP level might reflect expan-
sion of macroscopic hepatic vascular invasion [25].
These findings suggest that the first goal of therapy for
advanced HCC with major PVTT should consist of
intensive treatment to recanalize the PVTT. RT is more
effective than sorafenib, because major PVTT is inten-
sively irradiated by RT. In fact, the overall objective re-
sponse rate (complete response plus partial response)
for PVTT by RT reached 45%, and the response rate
was even better in patients with C-P class A [17]. In
addition, 3D-CRT for PVTT can minimize liver-related AEs
(Table 3). Almost all patients receiving sorafenib discontin-
ued therapy (due to AEs or disease progression), while only
one patient discontinued RT. Involvement of the main
PVTT is associated with poor prognosis, possibly because
of increased risk of tumor spread, elevated portal venous
pressure causing variceal hemorrhage, and decreased portal
flow resulting in ascites, jaundice, hepatic encephalopathy,
and liver failure [7,9,23,26]. Sorafenib can compromise
hepatic function by decreasing portal blood flow, as we pre-
viously demonstrated that sorafenib induced significant
vasoconstriction of the portal venous area and significantly
reduced portal venous flow, according to Doppler ultrason-
ography in patients with unresectable HCC [27]. Other in-
vestigators have used magnetic resonance imaging to show
similar results [28]. Therefore, we believe that sorafenib
should be administered only after recanalization of major
PVTT by other treatments [9].
The optimal treatment regimen for patients with unre-
sectable HCC and PVTT remains to be established. C-P
class A hepatic function is likely related to the treatment
response and survival, because it was previously identified
as one of the factors contributing to OS in various treat-
ments for HCC. Furthermore, we previously reported that
C-P class A hepatic function was related to the response to
RT [17]. Conversely, patients with C-P class B hepatic func-
tion tend to have a poor response to treatment, because
treatments often further impair hepatic function.
Limitations of the current study include the small study
population, as the number of patients with HCC andmajor PVTT is relatively small in the general population.
Furthermore, this was a non-prospectively randomized
study, and the evaluation of responsiveness to sorafenib
may have been incomplete due to the involvement of dif-
ferent institutions. Therefore, OS and contributing factors
were analyzed by PS analysis.
Conclusions
First-line therapy for unresectable HCC with PVTT should
consist of RT rather than sorafenib. Sorafenib should be in-
troduced after recanalization of PVTT by other treatments,
including RT. Multidisciplinary therapies based on individ-
ual hepatic function are expected to improve outcomes in
the future.
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